Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study.

摘要: This randomized, evaluator-blind, 3-arm parallel, comparator controlled, multicenter pilot study evaluated the safety and efficacy of ciclopirox nail lacquer topical solution, 8% in combination with oral terbinafine for treatment moderate to severe toenail onychomycosis (> or =60% disease involvement target and/or lunula/matrix involvement) (N = 73). Patients were randomized 1 3 arms: once daily 48 weeks plus 4 250 mg/day, followed by rest (no terbinafine), then another mg/day (PLs); 12 (PL12); (L12). At week 48, mycological cure (negative microscopy culture) occurred 66.7% (14/21) (PL8), 70.4% (19/27) (PL12), 56.0% (14/25) (L12) patients confirmed dermatophyte positive, respectively (P: not significant). this time point, effective (simultaneous > =90% reduction area) was observed 40.0% (8/20), 33.3% (8/24), 34.8% (8/23) patients, The PLs regimen well-tolerated had high compliance. data suggest that therapy (PL8) may be an alternative continuous onychomycosis.